Physician profile
Tammy Wall
NPI 1245348358
$3,945.89
in general payments reported to CMS, 2019-2025
30 companies · $266 in 2025
The $266 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $182 · 2022: $668 · 2023: $1,499 · 2024: $1,330 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,056 · Education: $39.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,055.63 |
| Education | $39.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $835.59 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $702.51 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $632.83 | 2021-2024 | |
| Pfizer INC. | $296.19 | 2022-2025 | |
| Glaxosmithkline, LLC. | $225.70 | 2022-2025 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $132.23 | 2021-2025 | Belsomra, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.10 | 2022-2024 | Jardiance, Tradjenta, Ofev |
| Sanofi-Aventis U.S. LLC | $107.93 | 2022-2023 | |
| Dexcom, INC. | $91.53 | 2021-2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $87.45 | 2022-2023 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $85.62 | 2021-2023 | Trintellix |
| Amgen INC. | $83.89 | 2022-2023 | Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $54.51 | 2024 | Rexulti |
| Amarin Pharma, INC. | $51.95 | 2021-2022 | |
| Exact Sciences Corporation | $49.90 | 2023-2025 | Cologuard Collection Kit |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $47.68 | 2023-2024 | |
| Axsome Therapeutics, INC. | $46.69 | 2024 | Auvelity |
| Abbott Laboratories | $42.48 | 2024-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $34.57 | 2024 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $33.04 | 2022 | |
| Esperion Therapeutics, INC. | $29.90 | 2021-2024 | Nexletol |
| Shield Therapeutics INC | $29.58 | 2023-2024 | Accrufer |
| Halozyme INC | $24.64 | 2023 | |
| Phathom Pharmaceuticals, INC. | $24.31 | 2025 | Voquezna |
| Astrazeneca Pharmaceuticals Lp | $18.37 | 2024 | Breztri |
| Janssen Pharmaceuticals, INC | $17.76 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.98 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.96 | 2024 | Xifaxan, Trulance |
| Sumitomo Pharma America, INC. | $14.61 | 2024 | Gemtesa |
| Intuitive Surgical, INC. | $1.39 | 2023 | Da Vinci Surgical System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tammy Wall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.